Drugmaker AbbVie says its new, multipill hepatitis C treatment has been approved for patients in the 28 European Union member countries. The company, based in North Chicago, Illinois, says the European Commission granted marketing authorization for its treatment consisting of Viekirax and Exviera.

Click here to read original article